RALLYBIO CORPORATION Debt Securities, Available-for-sale, Amortized Cost
RALLYBIO CORPORATION (RLYB) had Debt Securities, Available-for-sale, Amortized Cost of $65.98 million as of 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-26
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $65.98M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $21.88M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $30.54M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $36.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $65.98M S-4/A · filed 2026-08-26 |
| 2026-03-31 | $21.88M S-4 · filed 2026-07-15 |
| 2025-12-31 | $30.54M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $36.14M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $41.71M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $49.45M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $60.24M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $68.53M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $81.96M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $85.07M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $101.95M 10-K · filed 2025-03-13 |
| 2023-09-30 | $108.60M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $119.93M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $130.12M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $128.88M 10-K · filed 2024-03-12 |
| 2022-09-30 | $96.62M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $100.76M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $100.78M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |